

**EudraCT ID:** 2017-000675-90

**Product:** Romozosumab

**Amgen Study ID:** 20160397

**Protocol Title:** A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Sequential Therapy

**Status of Trial:** Cancelled

**Reason:** Trial was not started due to being cancelled.